Updated:
Upcoming UCB dividendNo official announcement has been made by UCB about dividends for the year 2026.
On May 6, 2026, UCB made a dividend payment of 1.45 euros to its shareholders.
UCB S.A., listed on the stock exchanges of Brussels, Frankfurt, Vienna, BATS EU, OTC market, London and TradeGate, recognized with the stock exchange symbol UCB, has a track record of more than twenty years paying dividends to its shareholders without suspensions, starting in 1999 and has remained stable and consistent to date.
The value of the amount delivered has been maintained in a very approximate range for several periods, being settled in a single annual installment, usually granted in the first days of May, reaching a yield of approximately 1.20%.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio UCB Dividends
- Payout Ratio12.81%
- Retained Earnings87.19%
An appropriate payout ratio may vary depending on the industry, the company's growth stage and its financial health.
Dividend calendar of UCB
There is no Dividend Calendar of UCB defined for 2026.
For a company to have growing dividends by our standards, the annual dividend amount must have increased steadily for at least the last 5 years.
The company's dividend yield is compared to the industry average to determine its positioning.
Imagine you have a list of dividend yields for different companies in an industry. If you look for the "top 25% percentile", you will find a number. This number tells you that the top 25% of the companies with the highest dividends have a yield higher than that number. On the other hand, the "top 75% percentile" shows you another number, which tells you that 75% of the companies have a higher yield than that number, thus showing a more common and less high yield.
For a company to have stable dividends by our standards, it is vital that it has not had an annual decline of more than 10% over the previous year.
Dividend history of UCB
In this table you can see the complete history:
| Year | Ex-Dividend | Amount | Total |
|---|---|---|---|
| 2026 |
05/04/2026 |
1.45 € |
1.45 € |
| 2025 |
04/25/2025 |
1.39 € |
1.39 € |
| 2024 |
04/26/2024 |
1.36 € |
1.36 € |
| 2023 |
04/28/2023 |
1.33 € |
1.33 € |
| 2022 |
04/29/2022 |
1.3 € |
1.3 € |
| 2021 |
04/30/2021 |
1.27 € |
1.27 € |
| 2020 |
05/04/2020 |
1.24 € |
1.24 € |
| 2019 |
04/26/2019 |
1.21 € |
1.21 € |
| 2018 |
04/27/2018 |
1.18 € |
1.18 € |
| 2017 |
04/28/2017 |
1.15 € |
1.15 € |
| 2016 |
04/29/2016 |
1.1 € |
1.1 € |
| 2015 |
05/04/2015 |
1.06 € |
1.06 € |
| 2014 |
04/29/2014 |
1.04 € |
1.04 € |
| 2013 |
05/02/2013 |
1.02 € |
1.02 € |
| 2012 |
04/27/2012 |
1 € |
1.0 € |
| 2011 |
05/02/2011 |
0.98 € |
0.98 € |
| 2010 |
05/03/2010 |
0.96 € |
0.96 € |
| 2009 |
05/05/2009 |
0.92 € |
0.92 € |
| 2008 |
04/28/2008 |
0.92 € |
0.92 € |
| 2007 |
04/30/2007 |
0.9 € |
0.9 € |
| 2006 |
06/16/2006 |
0.88 € |
0.88 € |
| 2005 |
06/17/2005 |
0.86 € |
0.86 € |
| 2004 |
06/11/2004 04/21/2004 |
0.82 € 0.42765 € |
1.2477 € |
| 2003 |
06/13/2003 04/15/2003 |
0.8 € 0.350673 € |
1.1507 € |
| 2002 |
06/14/2002 04/17/2002 |
0.76 € 0.325014 € |
1.085 € |
| 2001 |
06/14/2001 |
0.64 € |
0.64 € |
| 2000 |
06/14/2000 |
0.5 € |
0.5 € |
Information about UCB
UCB S.A., a company dedicated to the health industry, specializing in the development of pharmaceutical products to treat serious, immunological and neurological diseases, with headquarters in Belgium, is present in 40 countries, with more than 8 thousand employees, registering 5.5 billion euros in sales in 2022.
It was founded in 1928 by Emmanuel Janssen, which was initially dedicated to the creation of industrial chemicals, being one of the first to distill ammonia from coal, also including a pharmaceutical laboratory, in 1950 created a research and development center where they produce key drugs for the company as Atarax, Piracetam or Nootropil and Zyrtec or cetirizine.
In 2002 they merged their previous activities and added others such as the creation of resins and additives, splitting the chemicals division in 2004, when they acquired the biotechnology company Celltech, in 2019 they bought Ra Pharma, a specialist in immunological diseases, and in 2022 they acquired Zogenix, remaining exclusively in the pharmaceutical sector.
The main products for which UCB is recognized are Atarax, Briviact, Nootropil, Zyrtec and Xyzal antihistamines, Keppra and Cimzia anticonvulsant drugs for the treatment of epilepsy, Vimpat an anticonvulsant, Atamet and Neupro used for Parkinson's disease.
Frequently asked questions about UCB dividends
UCB pays dividends on a Annual basis.
UCB is listed on the Bolsa de Bruselas and is part of the BEL20.
UCB has the Ticker or stock code UCB.
The CEO of UCB in 2026 is Dr. Jean-Christophe Tellier.
The ISIN of UCB is BE0003739530.
UCB has a growing dividend program. In the last 5 years, dividends have been at least equal to or higher than the previous year.
Check the latest comments and participate in the live chat on UCB stocks (UCB).
No comments yet. Be the first to join in.